Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark

Thea Tanderup Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers · 2026

Read Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark by Thea Tanderup Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634386.txt.

Description

Rationale & ObjectiveChronic kidney disease (CKD) is a growing burden worldwide and in Denmark, with substantial clinical and economic consequences. Although national guidelines recommend sodium/glucose transporter 2 inhibitors (SGLT2i) for patients with CKD, type 2 diabetes (T2D) or heart failure (HF), underdiagnosis limits the use of SGLT2i.

Catalog record

CREATORThea Tanderup Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13634386

Browse the full library · About the Tower of Babel